Sclerostin in particular has received great attention in the last decade as it is an inhibitor of Wnt/Lrp signaling, and the target of the neutralizing monoclonal Ab romosozumab35, a drug recently approved to treat osteoporosis. Here, SOST is linked to osteoporosis.